CDK1 protein offers clues to which breast cancers will resist targeted therapy
Researchers at the Garvan Institute of Medical Research have discovered that the activity of a protein called CDK1 in breast cancers is linked to how they respond to a common therapy—an insight that could inform more personalized treatment approaches for patients.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Study reveals how congenital anomalies and deprivation impact children's educational achievement
United Kingdom
-
Platelets may play an unexpected role in glioblastoma progression
United Kingdom
-
Alcohol use held steady among cancer survivors
United Kingdom
-
Beyond treating symptoms: Life stories support mental health recovery
United Kingdom
-
New Texas School Is Named For Longtime Janitor ‘Miss Marilyn’ (Watch Her Reaction)
United Kingdom
-
Safer solutions: The urgent connection between smoking and HIV
United Kingdom
-
Hospitalized medical patients may fare better when treated by female physicians, study finds
United Kingdom
-
One in four Americans have exaggerated or made up symptoms to try to get antibiotics
United Kingdom